Several ASX-listed companies are making significant strides in their phase III clinical trials, the critical final stage ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...

Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals has submitted a Marketing ...

Acadia Pharmaceuticals Inc., a company is advancing breakthroughs in neuroscience to elevate life, announced that the company has submitted a Marketing Authorization Application (MAA) to the European ...

The news: The Australian sharemarket ended lower ahead of the release of labour force data on Thursday that could give clues as to the direction of the Reserve Bank's next monetary policy decision.

This announcement revealed that Neuren's partner, Acadia Pharmaceuticals, has submitted a marketing authorization application to the European Medicines Agency for its trofinetide treatment.

ASX ticks up ahead of US CPI report, Bitcoin hits $97K, while iron ore and real estate lead the charge. Overnight, Wall Street had a mixed session, with the blue-chip focused Dow Index rising by 0 ...

Neuren said Acadia anticipates potential approval in Q1 CY26. If granted marketing authorisation, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union.

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment of Rett syndrome Compumedics achieves a record $32.8m in sales orders in ...